<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634295</url>
  </required_header>
  <id_info>
    <org_study_id>130HT11P</org_study_id>
    <nct_id>NCT01634295</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of CKD-828 to Stage 2 Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of S-Amlodipine and Telmisartan(CKD-828) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of present study is to evaluate the efficacy and safety of two dose combination of
      S-Amlodipine/Telmisartan (2.5/40mg, 2.5/80mg and 5/80mg) compared with S-Amlodipine
      monotherapy (2.5mg and 5mg) in patients with Stage 2 hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  In patients with Stage 2 hypertension to determine the efficacy and safety of
           S-Amlodipine/Telmisartan (2.5/40mg, 2.5/80mg and 5/80mg) or S-Amlodipine monotherapy
           (2.5mg and 5mg) during 10 weeks.

        -  This study is consist of placebo run-in period(2 weeks_single blind) and treatment
           period(10 weeks_double blind.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Sitting systolic Blood Pressure (MSSBP)</measure>
    <time_frame>After 10 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting systolic Blood Pressure (MSSBP)</measure>
    <time_frame>After 2 weeks, 4 weeks and 6 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting diastolic Blood Pressure (MSDBP)</measure>
    <time_frame>After 2weeks, 4weeks, 6weeks and 10 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control Rate</measure>
    <time_frame>After 10 weeks of treatment</time_frame>
    <description>Sitting SBP&lt;140mmHg, Sitting DBP&lt;90mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>After 10 weeks of treatment</time_frame>
    <description>Reduction of Sitting SBP≥20mmHg, Sitting DBP ≥10mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>CKD-828 2.5/40, 2.5/80, 5/80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-Amlodipine 2.5, 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-828 2.5/40mg</intervention_name>
    <description>Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.
With the others investigation product placebo 4 tabs QD 2 weeks.</description>
    <arm_group_label>CKD-828 2.5/40, 2.5/80, 5/80mg</arm_group_label>
    <other_name>CKD-828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-828 5/40mg</intervention_name>
    <description>Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.
With the others investigation product placebo 4 tabs QD 2 weeks.</description>
    <arm_group_label>CKD-828 2.5/40, 2.5/80, 5/80mg</arm_group_label>
    <other_name>CKD-828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-828 5/80mg</intervention_name>
    <description>Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.
With the others investigation product placebo 4 tabs QD 6 weeks.</description>
    <arm_group_label>CKD-828 2.5/40, 2.5/80, 5/80mg</arm_group_label>
    <other_name>CKD-828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-amlodipine 2.5mg</intervention_name>
    <description>S-amlodipine 2.5mg QD 4 weeks
With the others investigation product placebo 4 tabs QD 4 weeks.</description>
    <arm_group_label>S-Amlodipine 2.5, 5mg</arm_group_label>
    <other_name>Anydipine S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-amlodipine 5mg</intervention_name>
    <description>S-amlodipine 2.5mg QD 6weeks
With the others investigation product placebo 4 tabs QD 6 weeks.</description>
    <arm_group_label>S-Amlodipine 2.5, 5mg</arm_group_label>
    <other_name>Anydipine S</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or older

          -  at the screening visit

               -  antihypertensive drugs not taking: 160mmHg ≤ sitSBP &lt; 200mmHg

               -  antihypertensive drugs taking: 140mmHg ≤ sitSBP &lt; 180mmHg

          -  at the randomization visit(160mmHg ≤ sitSBP &lt; 200mmHg)

          -  willing and able to provide written informed consent

        Exclusion Criteria:

          -  mean sitting DBP ≥ 120mmHg or mean sitting SBP ≥ 200mmHg at the screening visit and
             randomization visit

          -  for the past four weeks based on beginning of administration, patients took over four
             antihypertensive drugs

          -  known or suspected secondary hypertension(ex. aortic coarctation, Primary
             hyperaldosteronism, renal artery stenosis, pheochromocytoma)

          -  has severe heart disease(Heart failure NYHA functional class 3, 4), ischaemic heart
             diseasesstatus need to treatment, myocardiopathy, Valve disease, arrhythmia and so on
             and operated Coronary angioplasty

          -  has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6
             months

          -  Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as
             defined by fasting glucosylated hemoglobin(HbA1c) &gt; 8%)

          -  known severe or malignant retinopathy

          -  defined by the following laboratory parameters:

               -  hepatic dysfunction(AST/ALT &gt; UNL X 3)

               -  renal dysfunction(serum creatinine &gt; UNL X 1.5)

               -  hypopotassemia(K &lt; 3.0mmol/L) or hyperpotassemia (K&gt;5.5 mmol/L)

          -  acute or chronic inflammatory status need to treatment

          -  need to additional antihypertensive drugs during the study

          -  need to concomitant medications known to affect blood pressure during the study

          -  history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers

          -  known hypersensitivity related to either study drug

          -  history of drug or alcohol dependency within 6 months

          -  any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of investigational products(ex.
             gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass,
             active inflammatory bowel syndrome within 12 months prior to screening, gastric ulcers
             need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic function such
             as pancreatitis, obstructions of the urinary tract or difficulty in voiding)

          -  administration of other study drugs within 4weeks prior to randomization

          -  premenopausal women(last menstruation &lt; 1year) not using adequate contraception,
             pregnant or breast-feeding

          -  history of malignancy including leukemia and lymphoma within the past 5 years

          -  in investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-hoon An, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eun-joo Jo, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic university of Korea St. Paul's Hospitial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong-jin Kim, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung Hee university Hosipital at Gangdong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jang-ho Bae, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konyang University Hosipital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang-kyu Park, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-dae Kim, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chul-ho Kim, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sae-Joong Lim, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uk-Bum Phyun, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Women University Mokdong Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gyu-Rok Han, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangdong Sacred Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang Hyun Kim, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Boramae Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul national university Bundang Hospital</name>
      <address>
        <city>Bundang-gu</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD-828</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Stage 2 Hypertension</keyword>
  <keyword>S-Amlodipine</keyword>
  <keyword>Telmisartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

